腸疾患検査の世界市場（2022年～2029年）

世界の腸疾患検査市場は、腸疾患の症例の増加と検査技術の進歩により、成長が促進されています。

当レポートでは、世界の腸疾患検査市場について調査分析し、市場力学、セグメント分析、地域分析、競合情勢などを提供しています。

目次

第1章 範囲と調査手法

第2章 主な動向と発展

第3章 エグゼクティブサマリー

第4章 市場力学

• 市場に影響を与える要因
  • 促進要因
  • 抑制要因
  • 機会
• 影響分析

第5章 業界分析

• ポーターのファイブフォース分析
• バリューチェーン分析
• 特許分析
• 規制分析

第6章 COVID-19分析

• 市場におけるCOVID-19の分析
  • COVID-19前の市場シナリオ
  • 現在のCOVID-19市場シナリオ
  • COVID-19後または将来のシナリオ
• COVID-19中の価格変動
• 需給スペクトル
• パンデミック中の市場に関連する政府のイニシアチブ
• メーカーの戦略的イニシアチブ

第7章 適応疾患別

• 細菌性腸疾患
• ウイルス性腸疾患
• 寄生虫性腸疾患

第8章 検査方法別

• イムノアッセイ検査
• 従来の検査
• 分子診断検査

第9章 エンドユーザー別

• 病院
• 診断研究所
• 診察室

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他の欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他のアジア太平洋
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 競合企業の戦略分析
• 市場ポジショニング/シェア分析
• 合併と買収の分析

第12章 企業プロファイル

• Meridian Bioscience, Inc.
• Bio-Rad Laboratories, Inc.
• Alere, Inc.
• bioMerieux SA
• Trinity Biotech plc
• DiaSorin SpA
• Quest Diagnostics
• Coris BioConcept
• TECHLAB, Inc.
• Pro-Lab Diagnostics, Inc.

第13章 DataM

Market Overview

Enteric disease testing market is projected to grow at a CAGR of 1.9% during the forecast period (2022-2029). Enteric diseases are majorly caused by micro-organisms such as viruses, bacteria, and parasites that cause intestinal illness. These diseases are mostly caused due to the consumption of contaminated food and water, and some can spread from person to person. Enteric diseases have symptoms like nausea, vomiting, diarrhea, or fever.

An increase in the prevalence of different enteric diseases infection can lead to severe healthcare burden and a rise in the number of deaths in such patients. One of the important ways to avoid such situations is the timely detection of enteric diseases. Owing to this factor, there has been a rise in demand for rapid diagnostic tests for the enteric disease. Gastrointestinal pathogen panels are used to test the disease-causing viruses, parasites, and bacteria in stool samples and help, diagnose digestive system infection.

Market Dynamics:

Increasing cases of enteric disease and technological advancement of testing drives the market growth

The rising cases of enteric diseases and the cost-efficiency and rapidity of diagnostic systems are expected to drive demand for the diagnosis of enteric disease. For instance, according to the Centre for disease control and prevention, in 2020 the U.S., Salmonella bacteria caused approximately 1.35 million infections, 420 deaths, and around 26,500 hospitalizations. Contaminated food is the source in most cases. Salmonellosis is the second leading cause of foodborne illness in the U.S. Also, a traditional diagnostic procedure requires skilled staff and more time. The development in molecular technology increases the demand for molecular diagnostics. Thus, increasing demand for early diagnosis of these conditions is expected to drive the enteric disease testing market over the forecast period.

advancements such as gastrointestinal panel tests are used for identifying and qualitatively detecting multiple parasitic, bacterial, and viral nucleic acids in individuals with signs & symptoms of gastroenteritis or infectious colitis. The tests are performed on saliva and stool samples to generate rapid results for 15 pathogens in 6 hours. It is also used to test inherited food allergies to organisms such as Toxoplasma gondii and Entamoeba histolytica. This test has been approved by the U.S. FDA. Market players undergoing clinical studies to develop the new diagnostic test with high accuracy and high-performance delivery is anticipated to drive the market. For instance, in August 2019, QIAGEN published its multicenter clinical study in the European Journal of Clinical Microbiology & Infectious Diseases, demonstrating the accuracy of QIAstat-Dx syndromic testing for the diagnosis of acute gastroenteritis.

Market Segmentation:

Bacterial enteric disease segment accounted for the highest share in global enteric disease testing market

In 2021, Bacterial enteric disease segment had the highest revenue share of over XX percent. Bacterial enteric diseases are caused by bacteria that typically exist in the intestine of humans or animals. Enteric bacteria are either harmless, such as gut flora or microbiota, or pathogenic, which means that they cause disease. All bacteria are classified by a cell wall. By cell wall classification, there are two types of bacteria, gram-positive and gram-negative. Based on shape, bacteria are classified as rod, circular, or spiral-shaped. Gram-positive bacteria have several layers of peptidoglycan, a material made of sugars and amino acids, in their cell wall. Gram-negative bacteria have only one peptidoglycan layer. Various types of enteric bacteria can be further classified according to their cell wall type and shape. The majority of enteric bacteria are harmless and help to maintain a healthy intestinal tract, and these are generally referred to as gut flora or human micro biota. Other types of bacteria are pathogenic. They are causing illness.

For example, most strains of Escherichia coli are harmless, but the pathogenic strains of E.coli produce toxins that may lead to foodborne illnesses with various outcomes. Specific symptoms of an enteric bacterial infection vary based on the type of bacteria involved and the specific location of the infection. Common signs and symptoms include fever, diarrhea, vomiting, and abdominal pain. Treatment for individuals infected with pathogenic bacteria usually involves keeping them hydrated and, depending on the type of bacterial infection, considering antimicrobial therapy.

Geographical Penetration:

North America is the dominating region during the forecast period

In 2021, North America is expected to generate the highest market share in the forecast period. Major countries like Canada and US contribute the highest market share in forecast period. Despite efforts to reduce the presence of dangerous pathogens in Canadian food and water, Salmonella, E. coli, Campylobacter, Yersinia, Listeria, Shigella, Vibrio, Cryptosporidium, Cyclospora, Giardia, Norovirus, Rotavirus, and others continue to cause gastrointestinal, or enteric, disease in Canada.

According to the public health agency of Canada, one in eight Canadians gets sick with a domestically acquired foodborne illness. Most cases are mild and require only a day or two of reduced activities. Other severe cases can result in hospitalization, serious chronic conditions or death. The food net is launched to help answer the question of the true burden of enteric disease in Canadian communities and to help improve food and water safety in Canada.

These factors increase demand for the enteric disease testing market in Canada. Due to international travel, there is a growing prevalence of typhoid fever in the United States. This factor, coupled with the high emphasis on the investigation, tracking, and prevention of foodborne infections in the country, will stimulate the requirement of enteric infection treatment and testing in the region.

Competitive Landscape:

There are several established participants in the industry and local manufacturers; hence, the market is fragmented. Some major market players are Meridian Bioscience, Inc., Bio-Rad Laboratories, Inc., Alere, Inc., bioMerieux SA, Trinity Biotech plc, DiaSorin S.p.A., Quest Diagnostics, Coris BioConcept and TECHLAB, Inc. among others. In June 2021, SGS opened its new food testing laboratory in Papua New Guinea. SGS offers a comprehensive range of food safety, quality and sustainability services that help businesses grow consumer confidence and undertake informed risk-based decision-making. The laboratory offers a comprehensive range of testing services, including Food microbiology indicators, Food microbiology pathogens, Water microbiology and Water chemistry. Some major companies follow merger and collaboration strategies to expand their business. For instance, in July 2021, Intertek acquired JLA Brazil, a food testing company. JLA provides a range of microbiological, chemical testing and inspection services from its laboratories and sample collection points in Sao Paulo.

COVID-19 Impact:

Positive impact on the global enteric disease testing market

The increasing concern about the consumption of secure and safe food products due to the outbreak of COVID-19 increases the need for food testing across the globe. Moreover, pandemic situations created due to the outbreak of COVID-19 increased the demand for rapid tests from food manufacturers and growers to test an adequate number of samples in less time, thereby increasing the supply chain activities and enhancing the adoption of testing technologies. Increasing demand for enteric disease testing due to early disease diagnostics. An increase in the prevalence of different enteric diseases infection can lead to severe healthcare burden and a rise in the number of deaths in such patients. One of the important ways to avoid such situations is the timely detection of enteric diseases. Owing to this factor, there has been a rise in demand for rapid diagnostic tests. These factors fuel the opportunities in the global enteric disease testing market.

The global enteric disease testing market report would provide an access to approximately 61 market data tables, 52 figures and 170 pages

Table of Contents

Scope and Methodology

• 1.1. Research Methodology
• 1.2. Scope of the Market

2. Key Trends and Developments

3. Executive Summary

• 3.1. Market Snippet by Disease Indication
• 3.2. Market Snippet by Testing Methods
• 3.3. Market Snippet by End-user
• 3.4. Market Snippet by Region

4. Market Dynamics

• 4.1. Market impacting factors
  • 4.1.1. Drivers
  • 4.1.2. Restraints
  • 4.1.3. Opportunities
• 4.2. Impact analysis

5. Industry Analysis

• 5.1. Porter's five forces analysis
• 5.2. Value chain analysis
• 5.3. Patent Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives

7. By Disease Indication

• 7.1. Introduction
  • 7.1.1. Market size analysis, and y-o-y growth analysis (%), By Disease Indication Segment
  • 7.1.2. Market attractiveness index, By Disease Indication Segment
• 7.2. Bacterial Enteric Disease *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
• 7.3. Viral Enteric Disease
• 7.4. Parasitic Enteric Disease

8. By Testing Methods

• 8.1. Introduction
  • 8.1.1. Market size analysis, and y-o-y growth analysis (%), By Testing Methods Segment
  • 8.1.2. Market attractiveness index, By Testing Methods Segment
• 8.2. Immunoassay Testing *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
• 8.3. Conventional Testing
• 8.4. Molecular Diagnostic Testing

9. By End-user

• 9.1. Introduction
  • 9.1.1. Market size analysis, and y-o-y growth analysis (%), By End-user Segment
  • 9.1.2. Market attractiveness index, By End-user Segment
• 9.2. Hospitals *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
• 9.3. Diagnostic Laboratories
• 9.4. Physician Offices

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key region-specific dynamics
  • 10.2.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Disease Indication
  • 10.2.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Testing Methods
  • 10.2.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By End-user
  • 10.2.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. South America
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Disease Indication
  • 10.3.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Testing Methods
  • 10.3.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By End-user
  • 10.3.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
    • 10.3.6.1. Brazil
    • 10.3.6.2. Argentina
    • 10.3.6.3. Rest of South America
• 10.4. Europe
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Disease Indication
  • 10.4.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Testing Methods
  • 10.4.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By End-user
  • 10.4.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
    • 10.4.6.1. Germany
    • 10.4.6.2. U.K.
    • 10.4.6.3. France
    • 10.4.6.4. Spain
    • 10.4.6.5. Italy
    • 10.4.6.6. Rest of Europe
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Disease Indication
  • 10.5.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Testing Methods
  • 10.5.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By End-user
  • 10.5.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Disease Indication
  • 10.6.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Testing Methods
  • 10.6.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By End-user

11. Competitive Landscape

• 11.1. Competitive scenario
• 11.2. Competitor strategy analysis
• 11.3. Market positioning/share analysis
• 11.4. Mergers and acquisitions analysis

12. Company Profiles

• 12.1. Meridian Bioscience, Inc.*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. Bio-Rad Laboratories, Inc.
• 12.3. Alere, Inc.
• 12.4. bioMerieux SA
• 12.5. Trinity Biotech plc
• 12.6. DiaSorin S.p.A.
• 12.7. Quest Diagnostics
• 12.8. Coris BioConcept
• 12.9. TECHLAB, Inc.
• 12.10. Pro-Lab Diagnostics, Inc.
• List not Exhaustive*

13. DataM

• 13.1. Appendix
• 13.2. About us and services
• 13.3. Contact us